The Efficacy and Mechanism of Xuefu Zhuyu Decoction Combined with Tenofovir Dipyrfurate Fumarate Tablets in The Treatment of Liver Depression and Blood Stasis Type Hepatitis B Cirrhosis

Background: Cirrhosis is a chronic progressive liver disease. Hepatocyte injury leads to liver dysfunction. At present, antiviral drugs are mainly used to inhibit the replication of hepatitis virus to block liver fibrosis. Tenofovir disoproxil fumarate is a novel nucleotide reverse transcriptase inhibitor, which can eliminate hepatitis B virus and control the deterioration of chronic hepatitis B. Objective To investigate the efficacy and mechanism of Xuefu Zhuyu Decoction combined with tenofovir disoproxil fumarate tablets in the treatment of hepatitis B cirrhosis of liver depression and blood stasis. Methods A total of 150 patients with hepatitis B cirrhosis who were treated in our hospital from January 2019 to June 2021 with the dialectical type of "liver stagnation and blood stasis" were selected and divided into groups according to their treatment plan. 75 cases in the control group were given Fu Tenofovir disoproxil marate tablets were treated, and 75 patients in the observation group were treated with Xuefu Zhuyu Decoction combined with tenofovir disoproxil fumarate tablets. Count the total effective rates and adverse reactions of the two groups, record the scores of TCM syndromes, liver hemodynamics, fibrosis, liver function, hepatitis B virus deoxyribonucleic acid (HBV-DNA), MMP1, TIMP1, TIMP1/MMP1 changes. Results The curative effect of the observation group was higher than that of the control group, which was statistically significant (P<0.05). Compared with before treatment, the portal vein flow rate (PW) and intrahepatic circulation time (HV-HA) of the two groups increased (P<0.05), the portal vein congestion index (PV-CI) decreased (P<0.05), and the portal vein diameter (PVD) Compared with before treatment, the difference was not statistically significant (P>0.05). After treatment, PW and HV-HA in the observation group were higher than those in the control group (P<0.05), and PV<I was lower than that in the control group (P<0.05). Compared with the control group, the difference was not statistically significant (P>0.05). Compared with before treatment, the scores of the two groups of chest and hypothermia distended, abdominal distension, mental fatigue, depression, irritability, and amitrati decreased (P<0.05). The scores of TCM syndromes of the observation group were lower than those of the control group (P<0.05). P<0.05). Compared with before treatment, the two groups of matrix metalloproteinase 1 (MMP1) increased (P<0.05), laminin (LV), type IV collagen (IV-C), type III procollagen (PCIHT, hyaluronic acid (P<0.05) HA), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), TIMP1/MMP1, alanine aminotransferase (ALT), aspartate aminotransferase (AST), HBV-DNA decreased (P<0.05), observe After treatment, MMP1 in the group was higher than that in the control group (P<0.05), and fibrosis indexes, liver function indexes, TIMP1, TIMP1/MMP1, and HBV-DNA were lower than those in the control group (P<0.05). The adverse reactions between the two groups were not statistically significant (P>0.05). Conclusion Xuefu Zhuyu Decoction combined with tenofovir disoproxil fumarate tablets is effective in treating hepatitis B cirrhosis of liver depression and blood stasis, and its mechanism may be related to improving liver hemodynamics, regulating fibrosis, liver function and other indicators related.

Systematic Analysis of tRNA-Derived Small RNAs Reveals Effects of Xuefu-Zhuyu Decoction on Hippocampus of Rats after Traumatic Brain Injury

Background: Traumatic brain injury (TBI) is one of the most common neurosurgical diseases which refers to brain function impairment or brain pathological changes induced by external causes. A traditional Chinese medicine, Xuefu Zhuyu Decoction (XFZYD), has been indicated to harbor therapeutic property against TBI. Transfer RNA (tRNA)-derived small RNAs i.e., tsRNAs (a group of small RNAs derived from tRNAs) are multifunctional regulatory non-coding RNAs generated under pressure and implicated in the progression of TBI.Methods: TBI model was successfully constructed by using of rats. Further using sequencing and omics to identify novel tsRNAs as drug targets for XFZYD therapy against TBI in rat hippocampus. qPCR assay was used to further verify the experimental results. GO analyzed the signaling pathways of downstream target genes of tsRNA in XFZYD regulated TBI model. qPCR was used to detect the influence of over-expressed tsRNA mimic/inhibitor on their target genes in PC12 cell.Results: Our RNA-Seq data illustrates that 11 tsRNAs were mediated by the XFZYD. The experimental data revealed AS-tDR-002004 and AS-tDR-002583 as potential targets for XFZYD therapy and influenced TBI via the cadherin signaling pathway, cocaine addiction, circadian entrainment and nicotine pharmacodynamics pathway. We also confirm that Pi4kb, Mlh3, Pcdh9, and Ppp1cb were targets genes of 2 XFZYD regulated tsRNAs in hippocampus of rat model and PC12 cells. Furthermore, biological function analysis revealing potential therapeutic effects of tsRNAs, and results found Mapk1, Gnai1 was the related genes of for XFZYD therapy against TBI.Conclusion: Our work successfully illuminates the efficiency of XFZYD for the treatment of TBI. The experimental data revealed AS-tDR-002004 and AS-tDR-002583 as potential targets for XFZYD therapy and influenced TBI via the cadherin signaling pathway, cocaine addiction, circadian entrainment and nicotine pharmacodynamics pathway in TBI rat model.

Research on Effect and Mechanism of Xuefu Zhuyu Decoction on CHD Based on Meta-Analysis and Network Pharmacology

Xuefu Zhuyu Decoction (XFZY) is an ancient compound widely used in the treatment of coronary heart disease. However, its efficacy evaluation is not complete and its mechanism of action is not clear enough. In an attempt to address these problems, the efficacy was evaluated by meta-analysis and the mechanism was elucidated by the network pharmacology method. We systematically searched relevant studies in PubMed, Chinese National Knowledge Infrastructure Database (CNKI), Cochrane Library, Wanfang Data, and other databases from 2007 to 2019. The association between XFZY treatment and CHD was estimated by risk ratio (RR) and corresponding 95% confidence intervals (95% CIs). The compounds and the potential protein targets of XFZY were obtained from TCMSP, and active compounds were selected according to their oral bioavailability and drug similarity. The potential genes of coronary heart disease were obtained from TTD, OMIM, and GeneCards. The potential pathways related to genes were determined by GO and KEGG pathway enrichment analyses. The compound-target and compound-target-pathway networks were constructed. Molecular docking validates the component and the target. A total of 21 studies including 1844 patients were enrolled in the present meta-analysis, indicating that XFZY has a greater beneficial on total effect (fixed effect RR = 1.30; 95% Cl: 1.24–1.36; P = 0.82 ; I2 = 0.0%) and electrocardiogram efficacy (fixed effect RR = 1.40; 95% Cl: 1.26–1.56; P = 0.96 ; I2 = 0.0%) compared with the control group. A total of 1342 components in XFZY were obtained, among which, 241 were chosen as bioactive components. GO and KEGG analyses got top 10 significantly enriched terms and 10 enriched pathways. The C-T network included 192 compounds and 3085 targets, whereas the C-T-P network included 10 compounds, 109 targets, and 5 pathways. There was a good binding activity between the components and the targets. XFZY has the curative effect on coronary heart disease, and its mechanism is related to 10 compounds, 10 core targets, and 5 pathways.

Anti-Inflammatory Mechanisms of Xuefu Zhuyu Decoction in The Treatment of Atherosclerosis Based on Network Pharmacology and Microarray Data Differences Analysis

Background: Xuefu Zhuyu decoction is a traditional Chinese formula composed of eleven herbs, which has the effect of promoting blood circulation and removing blood stasis. In this study, the anti-inflammatory mechanisms of Xuefu Zhuyu decoction in the treatment of atherosclerosis were studied utilizing network pharmacology, data mining, microarray data differences analysis and molecular docking.Methods: Analyzing data from the TCMSP, the effective components and key targets of Xuefu Zhuyu decoction were screened out. Atherosclerosis-related genes were extracted from the disease databases and determined according to differences analysis. The component-target network was constructed and gene enrichment analysis, as well as topology analysis, were carried out. Finally, the affinity between the target and the effective components was verified by molecular docking.Results: We screened 186 effective components of Xuefu Zhuyu decoction from TCMSP and obtained 126 targets. Through searching the disease databases and analyzing the results of differences analysis, two hundred and one atherosclerosis-related genes were obtained. After constructing the component-target network, it was found that Xuefu Zhuyu decoction played an anti-atherosclerotic role by acting on 21 targets. The results of enrichment analysis suggested that 21 key targets were mainly enriched in biological processes such as leukocyte adhesion and endothelial cell proliferation. The results of molecular docking showed that the key components of Xuefu Zhuyu decoction, have a good affinity with IL-6 and VEGFA.Conclusions: Our bioinformatics analyses suggest that Xuefu Zhuyu decoction plays an anti-atherosclerotic role by regulating biological processes such as leukocyte adhesion and endothelial cell proliferation. This study provides a theoretical basis for the further study of the indications of Xuefu Zhuyu decoction and the development of anti-atherosclerotic drugs.